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Background. Since the treatment of hypertension is beneﬁcial for the elderly, we have undertaken this study that aims to evaluate
the management of hypertension in elderly patient in Cˆ ote d’Ivoire. Methods. A retrospective study was conducted among 854
hypertensive elderly patients of Abidjan Cardiology Institute who were followed for a minimum of one year, between January
2000 and December 2009. Results. The patients mean age was 73.1 ± 5.3 years, and 59% were women. At the ﬁrst presentation, it
was mostly systolic-diastolic hypertension (51.8%) and isolated systolic hypertension (38.5%). Mean blood pressure was 169.4 ±
28.4mmHg for systolic, 95.3±15.7mmHg for diastolic, and 74.1±22.8mmHg for pulse pressure. Pulse pressure was ≥60mmHg
in 80.4%. According to the European Guidelines stratiﬁcation of the cardiovascular risk-excess attributable to high blood pressure,
82.1% of the sample had a very high added risk. The pharmacological therapy was prescribed in 93.5%. More than 66% of patients
were receiving ≥2 antihypertensive drugs including ﬁxed-dose combination drugs. The most common agents used were diuretics
(63.5%) followed by angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in 61.3%. The most common
agents used for monotherapy were calcium antagonists. When ≥2 drugs were used, diuretics and angiotensin-converting enzyme
inhibitors or angiotensin receptor blockers were the most common. Blood pressure control was achieved in 42.6%. Conclusion.
The control of elderly hypertension can be eﬀective in Sub-Saharan Africa. He required at least two antihypertensive drugs to meet
the recommended blood pressure target.
1.Introduction
Hypertension is an important worldwide public-health
challenge because it is one of the most common chronic
conditions [1, 2]. The prevalence of hypertension in Sub-
Saharan Africa is between 12.5 and 26.9% [3]. In 2005 the
World Health Organization stepwise approach to surveil-
lance of noncommunicable diseases risk factors established
prevalence of hypertension in Cˆ ote d’Ivoire to 21.7% [4].
Hypertension is a major risk factor for cardiovascular
(CV) disease [5–7]. It remains an important cause of
coronary heart disease, cerebrovascular disease, peripheral
artery disease, and heart failure [8].
Age is the most powerful risk factor for hypertension,
death, and cardiovascular death [9]. The worldwide increase
in the elderly population (age ≥ 65 years) is associated with
concurrent increases in prevalence of systemic hypertension
and morbidity and mortality from vascular complications of
hypertensive disease [10].
Recently, numerous large clinical trials have provided
evidence of the beneﬁts of reducing BP in the elderly.
Meta-analysis of clinical trials showed that treatment of
hypertensioninolderadultsisasbeneﬁcialasthatinyounger
adults [11, 12]. It is well established now that the treatment
of hypertension in elderly patient was associated with a
reduction in the rate of fatal or nonfatal stroke, a reduction
in the rate of death from stroke, a reduction in the rate of
death from any cause, a reduction in the rate of death from
cardiovascular causes, and a reduction in the rate of heart
failure [12, 13].
There are few Sub-Saharan African data about man-
agement of hypertension in elderly. It was in this context
that we undertook the present study at Institute of Cardi-
ology of Abidjan, the single university hospital managing2 International Journal of Hypertension
cardiovascular diseases in Cˆ ote d’Ivoire. This study aims to
describe characteristics, risk factors, treatment and control
of blood pressure of elderly hypertensive patients.
2. Methods
We undertook a retrospective descriptive study involving
patients seen at the outpatient clinics of the Institute of
Cardiology of Abidjan. The study period spans 10 years,
between January 2000 and December 2009. The study
population was hypertensive elders (aged at least 65 years)
with a regular followup at the Institute of Cardiology of
Abidjan within one year. This series includes patients who
had been on an initial treatment upon referral to our center.
Data were collected from the information contained in
medical records.
We used the deﬁnition and classiﬁcation hypertension
standards of the European Society of Hypertension (ESH)
and the European Society of Cardiology (ESC) [7]. We have
separated the systolic-diastolic hypertension from isolated
systolic hypertension and from isolated diastolic hyperten-
sion. Pulse pressure has been considered pathological when
it was ≥60mmHg. The data collected were age, sex, blood
pressure at initial presentation and during the followup
(one month, 2 months, 3 months, 6 months, 1 year or
last presentation), the coexistence of other cardiovascular
risk factors, the impact of hypertension, and the treatment
modalities. The following additional CV risk factors were
document when present: current smoking, dyslipidaemia,
diabetes, and obesity. Obesity was deﬁned by a body mass
index over 30kg/m2. Waist circumference was recorded
when available. Dyslipidaemia was deﬁned according to
our biochemistry laboratory standard when the level of
total cholesterol was >2g/dL, LDL-cholesterol >1.4g/dL, or
HDL-cholesterol <0.4g/L. Diabetic patients were informed
and treated for diabetes as per standard clinical practice.
New diabetic patients detected at Institute of Cardiology
of Abidjan were diagnosed based on the standard value
in our laboratory, fasting plasma glucose >1.26g/dL on
repeated measurement. The overall management of diabetes
was coordinated by the individual patient’s physician and
not by the Cardiology staﬀ of Institute of Cardiology of
Abidjan. The assessment of the impact of hypertension has
systematically included electrocardiogram and plasma crea-
tinine. All strokes were documented by a brain computerized
tomography scan imaging. Echocardiogram was frequently
performed, and the results were included in the data
collection. Finally, when other tests were seldom performed
(e.g., albuminuria, microalbuminuria, the fundscopy, and
24-hour ambulatory blood pressure), they were not used for
analysis.
The ESH and ESC categorization of total risk as low,
moderate, high, and very high added risk has the merit of
simplicity and was, therefore, chosen for risk stratiﬁcation
[7]. In addition, we focused on the evolution of blood pres-
sureduringfollowup.Bloodpressurecontrolwasdeﬁnedasa
treated blood pressure <140mmHg systolic and <90mmHg
diastolicandwasascertainedbydirectmeasurementofblood
pressure.
Table 1: Population distribution according to the classiﬁcation of
bloodpressure,theothercardiovascularriskfactor,andtargetorgan
damage at ﬁrst presentation.
Clinical data %
Classiﬁcation of blood pressure
Controlled blood pressure 9.2
Systolic and diastolic hypertension (51.8%)
Grade1 hypertension 4.8
Grade 2 hypertension 14.7
Grade 3 hypertension 32.3
Isolated systolic hypertension (38.5%)
Grade1 hypertension 16.8
Grade 2 hypertension 12.7
Grade 3 hypertension 9
Isolated diastolic hypertension 0.5
Other cardiovascular risk factor
Dyslipidemia 56%
Diabetes 18.6
Smoking 23.7
Obesity 33.8
Abnormal pulse pressure 80.4
Organ damage
No organ damage 36.3
One organ damage
Cardiovascular 37.9
Neurological 9.8
Renal 2.7
More than one organ damage
Cardiovascular + renal 8.5
Cardiovascular + neurological 3.1
Renal + neurological 0.6
Cardiovascular + neurological + renal 1.1
DataanalysiswasconductedusingIBMSPSSStatistics17
software. Univariate analysis was performed for signiﬁcant
associations.AP valueof ≤0.05wasconsideredforstatistical
signiﬁcance.
3. Results
During the study period, 2575 hypertensive Black Africans
patients have had a regular follow-up of at least one year.
Among these patients, 849 were elderly subjects. The mean
age was 73.1 ± 5.3 years (range 65–98 years), 59% were
female. At ﬁrst presentation blood pressure was inappropri-
ately controlled in 90.8% patients.
Itwasmostlysystolic-diastolichypertension(51.8%)and
isolated systolic hypertension (38.5%). Diastolic hyperten-
sion was observed in 0.5% (Table 1). Mean blood pressure
was 169.4 ± 28.4mmHg for systolic, 95.3 ± 15.7mmHg
for diastolic, and 74.1 ± 22.8mmHg for pulse pressure.
Blood pressure of men was not signiﬁcantly diﬀerent from
that of women (Table 2). Pulse pressure was ≥60mmHg inInternational Journal of Hypertension 3
Table 2: Type of drugs used.
Type of drug %
One drug (33.1%)
Calcium antagonists 36.3
RAS blockers 32
Diuretics 16
β-blockers 10.7
CAS 5
Two drugs (53.8%)
R A Sb l o c k e r s+D i u r e t i c s 6 9 . 8
β- b l o c k e r s+D i u r e t i c s 8 . 5
β-blockers + Calcium antagonists 7.4
Diuretics + Calcium antagonist 5.5
RAS Blockers + Calcium antagonists 3.5
RAS Blockers + β-blockers 3.5
C A S+( d i u r e t i c so rR A Sb l o c k e r so rc a l c i u m
antagonist or β-blockers) 1.8
Three drugs (11%)
RAS blockers + Diuretics + Calcium antagonists 51.7
R A Sb l o c k e r s+D i u r e t i c s+β-blockers 18.4
Diuretics + β-blockers + Calcium antagonists 17.2
RAS blockers + β-blockers + Calcium antagonists 2.3
Other using CAS 10.4
Four drugs (2.2%)
R A Sb l o c k e r s+D i u r e t i c s+C a l c i u ma n t a g o n i s t s
+ β-blockers 58.8
RAS blockers + Diuretics + Calcium antagonists+
CAS 35.3
R A Sb l o c k e r s+D i u r e t i c s+β-blockers+ CAS 5.9
RAS blockers: angiotensin-converting enzyme inhibitors or angiotensin
receptor blockers, CAS: Centrally acting sympatholytics.
80.4%. Overall, patients were diagnosed with hypertension
for an average of 4 ± 6.7 years (range 1–47) at the time of
their initial assessment in our clinics. The mean follow-up
duration in ICA was 3 ± 1 . 8y e a r s( r a n g e1t o1 8y e a r s ) .
Diabetes was found in 18.6% of patients. It was type 2
in 61.4%. At least one target organ damage was observed
in 50%. Isolated cardiac complications were the most
frequent (37.9%). The cardiovascular risk factors other than
hypertension and the results of target organ damage are
reported in Table 1. Habitual alcohol consume was found in
28.4%.
Echocardiography was performed in 50.2%. The record-
ed anomalies were a left ventricular diastolic dysfunction
(39.2%), hypertensive cardiomyopathy (32.1%) and minor
lesions (slight valve regurgitation, valvular sclerosis, valvular
calciﬁcation) (19.6%).
Application of the cardiovascular risk stratiﬁcation
according to the European Guideline for the management
o fa r t e r i a lh y p e r t e n s i o ni d e n t i ﬁ e dav e r yh i g ha d d e dr i s ki n
82.1%, a high added risk in 4.8%, a moderate add risk in
7.5% and a low add risk in 5.7%.
Table 3: Change in blood pressure for all patients.
Blood pressure
(mmHg) First presentation Last presentation P
SBP 169.4 ± 28.4 153.5 ± 26.1 <0.001
DBP 95.3 ± 15.7 87.1 ± 14.3 <0.001
PP 74.1 ± 22.7 66.5 ± 19.9 <0.001
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Figure 1: Changes in blood pressure during followup.
In addition to lifestyle changes, 93.5% of patients
received antihypertensive drugs (Table 2). Of those on
treatment for high blood pressure, the most common
agents used were diuretics in 63.5%, followed by blockers
of the renin-angiotensin system (RAS) in 61.3% (either
angiotensin converting enzyme inhibitors or angiotensin
receptor blockers), calcium antagonists (31.6%), β-blockers
(19%), and centrally acting sympatholytics (4.5%). Antihy-
pertensive drugs were used in monotherapy or combination
(Table 3). As a monotherapy, the most prescribed drug
class was calcium antagonists (36.3%), followed by RAS
blocker (32%). Polytherapy (more than 2 antihypertensive
drugs including ﬁxed-dose combination drugs) was used for
67% of patients on treatment for hypertension. The most
common combination of drugs among those taking 2 agents
was RAS blockers plus diuretics (69.8%).
Diabetic patients as well as those with kidney failure have
receivedsigniﬁcantlymoreRAS-blockersforthetreatmentof
hypertension than other patients (P = 0.03 for diabetic and P
= 0.04 for renal failure).
Between the ﬁrst and the last visit, blood pres-
sure decreased signiﬁcantly (Table 3). It was for systolic
blood pressure by 15.9mmHg, diastolic blood pressure by
8.2mmHg, and pulse pressure by 7.6mmHg. Hypertension
was controlled in 42.6% of patients.
Figure 1 shows changes in blood pressure during fol-
lowup. The sex (P = 0.88), age (P = 0.48), duration of treat-
ment of hypertension (P = 0.13), the number of consultation
(P = 0.13), and the duration of hypertension (P = 0.27) did
not inﬂuence the control of blood pressure. Hypertension4 International Journal of Hypertension
Table 4: Change in blood pressure by gender.
Blood
pressure
(mmHg)
Male Female P
SBP 171 ± 28.6 168.3 ± 28.3 0.28
First
presentation DBP 95 ± 16.3 95.4 ± 15.3 0.39
PP 76 ± 23.3 72.9 ± 22.3 0.24
SBP 155.4 ± 27.1 152.2 ± 25.4 0.88
Last
presentation DBP 87.9 ± 14.9 86.5 ± 13.9 0.89
PP 67.4 ± 19.5 65.7 ± 20.2 0.03
Control rate 39.2 45.0 0.88
DBP: Diastolic blood pressure, PP: Pulse pressure, SBP: Systolic blood
pressure.
was best controlled with multiple drugs therapy (1.7 drugs
forcontrolledpatientsascomparedto1.4fortouncontrolled
patients, P < 0.001). Pulse pressure was signiﬁcantly lowered
in females (P = 0.03) (Table 4).
4. Discussion
This study found that a signiﬁcant proportion of patients
(33%) who visit the ICA are elderly. In the elderly a
signiﬁcant part of hypertension is represented by systolic
hypertension. Increased arterial stiﬀness may increase car-
diovascular morbidity and mortality because of an elevation
of systolic blood pressure (SBP), which raises left ventricular
afterload, and because of a decrease in diastolic blood
pressure (DBP), which alters coronary perfusion [14]. These
elderly patients have a high pulse pressure (PP). Elevated PP
is a powerful independent predictor of cardiovascular end
points in the elderly [15–18].
According to Skurnick et al. [19], the PP levels of women
were lower than those of men in early adulthood and higher
in older ages. But in our study, although the diﬀerence was
not statistically signiﬁcant, the PP of men was higher than
women’s PP. Moreover, under hypertension treatment, the
PP of women had signiﬁcantly regressed compared to men’s.
Cardiovascular risk of our patients was very high in
most cases. As has been previously described, it is suggested
that Black Africans present more severe forms of arterial
hypertension and a greater risk of target organ damage [20–
23]. Overall, uncontrolled blood pressure remains the main
factor for target organ damage more frequently in Sub-
Saharan Africa compared to western countries [24].
The main beneﬁts of antihypertensive treatment are
blood pressure lowering per se, largely independent of the
drugs employed. Diuretics, β-blockers, calcium antagonists,
and RAS blockers can adequately lower blood pressure,
signiﬁcantlyimproving cardiovascularoutcome[25].Several
properties of the thiazide-type diuretics have led to them
being recommended as ﬁrst-line therapy in older adults
with uncomplicated stage 1 hypertension. At low doses
(<25mg/day of hydrochlorothiazide or equivalent), these
agents have been demonstrated in randomized controlled
trials to reduce mortality, stroke, and cardiovascular events
in the older hypertensive population [26]. There is good
synergy with agents of diﬀerent classes (RAS-blockers and
calcium antagonists) and most importantly in the elderly;
these drugs preferentially lower SBP relative to DBP. In
our study, diuretics have been widely prescribed. In our
environment, the added beneﬁt to of diuretics is their low
cost. RAS-blockers were also widely prescribed because of
comorbidities such as diabetes, left ventricle hypertrophy
or kidney failure, situations that required a preferential
indication of RAS-blockers. Furthermore, HYVET [12]
recommended the addition of a RAS-blocker in the event
of insuﬃcient control of BP. The RAS-blocker diuretic
combination was by far the most used in our study.
In monotherapy, calcium antagonists were the most
prescribed. Calcium antagonists have shown eﬀectiveness in
lowering BP in the older hypertensive patient. Signiﬁcant
reductions in stroke risk in older hypertensive patients
were demonstrated in the Systolic Hypertension Europe and
China Trials [27, 28]. Furthermore, results from patients
with very high cardiac risk enrolled in ACCOMPLISH
trial demonstrated the superiority of an ACEI-calcium
antagonists (amlodipine) combination over an ACE-thiazide
combination with regard to a decrease in cardiovascular
events despite comparable BP-lowering eﬀects [29].
In most cases, combination therapy was required for
our patients. According to Aronow [30] if blood pressure
is more than 20/10mmHg above the target BP, treatment
should be initiated with two antihypertensive drugs. In our
study, hypertension was best controlled with multiple drugs
therapy. One should certainly not hesitate to use more than
one antihypertensive drug even in elderly patients if the
target blood pressure is not reached. Particular attention
must be given to eventual side-eﬀects in elderly population.
Control rate of hypertension (42.6%) was acceptable in our
Sub-Saharan African context.
5. Study Limitation
There is no information on treatment tolerance, particularly
on orthostatic hypotension occurrence in the elderly often
polymedicated patients. This limit is due to the retrospective
nature of our study. Also in these elderly patients with
high cardiovascular risk, it would be interesting to describe
cardiovascular events occurred during the year-long or more
followup. Furthermore, the control rate of hypertension
obtained does not reﬂect the reality of the management of
hypertension in Cˆ ote d’Ivoire. There is certainly a bias due
to the method of recruitment of our population. Patients
who were regularly monitored for at least one year showed
probably best treatment adherence.
6. Conclusion
Despite the classical reduced life expectancy in Sub-Saharan
African population because of various illnesses, numerous
elderly people exist. One must deal with the speciﬁc healthInternational Journal of Hypertension 5
needs of the elderly. Their blood pressure is characterized
by the frequency of isolated systolic hypertension. Elderly
hypertensive patients have a very high cardiovascular risk.
Diuretics as recommended were the drugs most prescribed.
The control rate of hypertension was signiﬁcant, mostly at
the cost of combination therapy.
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